Supplements and Featured Publications
Treatment Trends in Adult and Pediatric Acute Lymphoblastic Leukemia
Volume: 1
Issue: 1
Bridging the Gaps With Bispecific Antibody Therapy in NSCLC
Volume: 1
Issue: 1
Treatment Trends and Ongoing Research in Acute Lymphoblastic Leukemia
Volume: 1
Issue: 1
Moving the Needle With JAK Inhibition in Myelofibrosis
Volume: 1
Issue: 1
Menin Inhibition Makes Waves for KMT2A-Rearranged AML
Volume: 1
Issue: 1
Integrating MDM2 Inhibition Into Myelofibrosis Management
Volume: 1
Issue: 1
Managing Ocular and Other Adverse Effects Associated With Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Volume: 1
Issue: 1
Dissecting Ongoing Research With Oncolytic Viruses in Melanoma
Volume: 1
Issue: 1
ASH 2024: Priority Report: Updates in Myeloproliferative Neoplasms
Volume: 1
Issue: 1
Experts detail updates in myeloproliferative neoplasms from the 2024 ASH Annual Meeting & Exposition.
Updates for BTK Inhibitors in CLL Around ASH 2024
Volume: 1
Issue: 1
Experts detail updates regarding BTK inhibitors in chronic lymphocytic leukemia around the 2024 ASH Annual Meeting.
Pancreatic Cancer Awareness Month: Updates in Ongoing Research in RAS Inhibition
Volume: 1
Issue: 1
Making the Most of MRD Assessment, Checkpoint Inhibition in Colorectal Cancer
Volume: 1
Issue: 1
Prostate Cancer Awareness Month: Updates in mCRPC and Radioligand Therapy
Volume: 1
Issue: 1
Exacting the Role of Novel Endocrine Therapies in ER+ Metastatic Breast Cancer
Volume: 1
Issue: 1
Taking Stock of Long-Term Data With TKIs in CML
Volume: 1
Issue: 1
Integrating the Glucocorticoid Receptor Pathway Into Ovarian Cancer Management
Volume: 1
Issue: 1
Harnessing the Activity of Targeted Therapy in HER2-Mutant NSCLC
Volume: 1
Issue: 1
ESMO 2024: Priority Report: Updates in Renal Cell Carcinoma
Volume: 1
Issue: 1
Research Efforts Seeking to Raise the Bar in Low-Risk MDS
Volume: 1
Issue: 1
Emerging Novel Therapies in Bladder Cancer
Volume: 1
Issue: 1
Novel Approaches in Treating HPV-Positive HNSCC
Volume: 1
Issue: 1
Research Efforts Are Underway in Advanced or Metastatic Epithelial Tumors
Volume: 1
Issue: 1
Unpacking Key Updates and Unmet Needs in Non–Clear Cell RCC
Volume: 1
Issue: 1
Examining the Novelty of Vaccine-Based Therapy in Metastatic Breast Cancer
Volume: 1
Issue: 1
ASCO 2024: Priority Report: Updates in RCC
Volume: 1
Issue: 1
Reviewing Key Updates in the Realm of HER2+ and HER2-Low Breast Cancer
Volume: 1
Issue: 1
Research Efforts Abound in the HCC Paradigm
Volume: 1
Issue: 1
EHA 2024: Priority Report: Updates in Myeloproliferative Neoplasms
Volume: 1
Issue: 1
Examining Recent Updates in ROS1+ NSCLC
Volume: 1
Issue: 1
Mapping Clinical Updates in Myelodysplastic Syndromes
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5